Literature DB >> 22238414

Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.

M Wagner1, S Wolf, F M Reischies, M Daerr, S Wolfsgruber, F Jessen, J Popp, W Maier, M Hüll, L Frölich, H Hampel, R Perneczky, O Peters, H Jahn, C Luckhaus, H-J Gertz, J Schröder, J Pantel, P Lewczuk, J Kornhuber, J Wiltfang.   

Abstract

OBJECTIVE: To compare cued recall measures with other memory and nonmemory tests regarding their association with a biomarker profile indicative of Alzheimer disease (AD) in CSF among patients with mild cognitive impairment (MCI).
METHODS: Data were obtained by the German Dementia Competence Network. A total of 185 memory clinic patients fulfilling broad criteria for MCI (1 SD deficit in memory tests or in nonmemory tests) were assessed with an extended neuropsychological battery, which included the Free and Cued Selective Reminding Test (FCSRT), the word list learning task from the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological battery (CERAD-NP), and the Logical Memory (LM) paragraph recall test from the Wechsler Memory Scale-Revised. CSF was obtained from all patients.
RESULTS: A total of 74 out of 185 subjects with MCI (40%) had a CSF profile consistent with AD (Aβ(1-42)/tau ratio; CSF AD+ group). FCSRT measures reflecting both free and cued recall discriminated best between CSF AD+ and CSF AD- patients, and significantly improved CSF AD classification accuracy, as compared with CERAD delayed recall and LM delayed recall.
CONCLUSIONS: Cued recall deficits are most closely associated with CSF biomarkers indicative of AD in subjects with MCI. This novel finding complements results from prospective clinical studies and provides further empirical support for cued recall as a specific indicator of prodromal AD, in line with recently proposed research criteria.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22238414     DOI: 10.1212/WNL.0b013e318245f447

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  51 in total

Review 1.  CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Authors:  Alessandro Stefani; Livia Brusa; Enrica Olivola; Mariangela Pierantozzi; Alessandro Martorana
Journal:  J Neural Transm (Vienna)       Date:  2012-05-24       Impact factor: 3.575

2.  Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.

Authors:  Kathryn V Papp; Rebecca E Amariglio; Elizabeth C Mormino; Trey Hedden; Maria Dekhytar; Keith A Johnson; Reisa A Sperling; Dorene M Rentz
Journal:  Neuropsychologia       Date:  2015-05-19       Impact factor: 3.139

3.  The free and cued selective reminding test distinguishes frontotemporal dementia from Alzheimer's disease.

Authors:  Raquel Lemos; Diana Duro; Mário R Simões; Isabel Santana
Journal:  Arch Clin Neuropsychol       Date:  2014-07-25       Impact factor: 2.813

Review 4.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Authors:  Kaj Blennow; Bruno Dubois; Anne M Fagan; Piotr Lewczuk; Mony J de Leon; Harald Hampel
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

5.  Two-stage screening for early dementia in primary care.

Authors:  Ellen Grober; Wenzhu Bi Mowrey; Amy R Ehrlich; Peter Mabie; Steven Hahn; Richard B Lipton
Journal:  J Clin Exp Neuropsychol       Date:  2016-06-07       Impact factor: 2.475

Review 6.  Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease.

Authors:  Elizabeth C Mormino; Kathryn V Papp
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  Plasma proteomics for the identification of Alzheimer disease.

Authors:  Liang-Hao Guo; Panagiotis Alexopoulos; Stefan Wagenpfeil; Alexander Kurz; Robert Perneczky
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

8.  Conventional and robust norming in identifying preclinical dementia.

Authors:  Ellen Grober; Wenzhu Mowrey; Mindy Katz; Carol Derby; Richard B Lipton
Journal:  J Clin Exp Neuropsychol       Date:  2015-09-01       Impact factor: 2.475

9.  Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease.

Authors:  Liang-Hao Guo; Panagiotis Alexopoulos; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-04-17       Impact factor: 5.270

Review 10.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.